OrbiMed’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

OrbiMed’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,578	Closed	-$1.41M	–	169
2020 Q3	$1.41M	Sell	10,578 -8,000	-43%	-$1.34M	0.02%	139
2020 Q2	$3.13M	Hold	18,578	–	–	0.04%	125
2020 Q1	$2.67M	Hold	18,578	–	–	0.04%	121
2019 Q4	$6.13M	Hold	18,578	–	–	0.09%	97
2019 Q3	$9.29M	Hold	18,578	–	–	0.18%	80
2019 Q2	$11.3M	Hold	18,578	–	–	0.17%	88
2019 Q1	$11.3M	Hold	18,578	–	–	0.18%	86
2018 Q4	$6.78M	Hold	18,578	–	–	0.13%	94
2018 Q3	$12.5M	Buy	18,578 +2,900	+18%	+$2.06M	0.15%	104
2018 Q2	$13.6M	Hold	15,678	–	–	0.16%	104
2018 Q1	$19.7M	Hold	15,678	–	–	0.24%	81
2017 Q4	$23.4M	Hold	15,678	–	–	0.3%	75
2017 Q3	$32.1M	Hold	15,678	–	–	0.31%	76
2017 Q2	$41.1M	Buy	15,678 +8,966	+134%	+$23.1M	0.43%	64
2017 Q1	$20.1M	Hold	6,712	–	–	0.23%	78
2016 Q4	$10M	Buy	6,712 +1,452	+28%	+$1.93M	0.13%	93
2016 Q3	$9.27M	Hold	5,260	–	–	0.11%	103
2016 Q2	$9.86M	Hold	5,260	–	–	0.1%	92
2016 Q1	$11.8M	Hold	5,260	–	–	0.12%	84
2015 Q4	$12.7M	Hold	5,260	–	–	0.11%	86
2015 Q3	$12.5M	Buy	+5,260	New	+$13.9M	0.13%	86

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

OrbiMed's NBRV Position: Q4 2020 in Review

OrbiMed sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2020, closing a stake of 10,578 shares — an estimated $1.41M sold.

OrbiMed first reported a position in NBRV in Q3 2015 and held it in 21 quarters. The position peaked at $41.1M in Q2 2017. 33 funds tracked by Wall St. Rank hold NBRV as of Q4 2020.

OrbiMed reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 10,578 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2020, an estimated $1.41M.
OrbiMed first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 21 quarters.
OrbiMed's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $41.1M in Q2 2017.
33 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.